All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

#ASCO23

Share:

Jun 2, 2023

X post image

6 Jun 2023

RT @szusmani: I have been asked several questions about the #ASCO23 abstract:
Durability of Responses With Biweekly Dosing of Teclistamab…

X post image

5 Jun 2023

#mmsm #ASCO23 https://t.co/UXsZiDwhCM

X post image

5 Jun 2023

@bhemato CARTITUDE-4: Patient characteristics and safety
#ASCO23 #MMSM @bhemato

X post image

5 Jun 2023

🚨LBA - CARTITUDE-4🚨
Cilta-cel vs PVd or DPd in patients with 1-3 prior lines
Median follow-up 15.9 months
@bhemato #ASCO23 #mmsm

X post image

4 Jun 2023

#ASCO23 | A total of 87 pts across elranatamab's trials had been exposed to ≥1 BCMA-directed therapy.
- ORR and PFS higher in prior CART vs ADC
- OS close to 1 yr, regardless of prior tx
- Similar safety profile as in BCMA-naive
‼️ CMV reactivation and PJP
By @AjayNookaMD #mmsm

X post image

4 Jun 2023

#ASCO23 | Katja Weisel (@UKEHamburg) shows the DREAMM-3 trial data while waiting for the results of belamaf in combination. Belamaf didn't negatively impact PFS2 or OS - more clarity with longer f-up and subsequent treatments #mmsm

X post image

4 Jun 2023

RT @Eddie_Cliff: Nice summary of myeloma CAR T-cell targets in different stages of development from Ivan Borrello

#ASCO23 #mmsm https://t…

X post image

4 Jun 2023

RT @HadidiSamer: #ASCO23 #mmsm @ASCO
Education session- Embracing Myeloma CAR-T
@paurotero

Sequencing per limited evidence suggest start…

X post image

4 Jun 2023

#ASCO23 | Hans Lee, @MDAndersonNews, shares the latest on linvoseltamab. ORR 71%, with 30% ≥CR at the RP2D; most patients quad-exposed. Lower rates of neutropenia potentially due to the de-escalation for pts in VGPR, but the most common cause of death was still infections. #mmsm

X post image

4 Jun 2023

#ASCO23 #mmsm https://t.co/FRfz7axBFc

X post image

4 Jun 2023

#ASCO23 | @DholariaMD presents an update of the ph I trial exploring the combination of talquetamab + daratumumab. This trial included patients refractory to anti-CD38 and previously exposed to bispecifics and #CARTs. The ph III (MonumenTAL-3) includes an arm with pom #mmsm

X post image

4 Jun 2023

#ASCO23 | Response rates with tecli + talque are high, with 61% of patients still on treatment.
The promising results in patients with EMD (soft tissue plasmacytomas) have led to opening an expansion cohort for further evaluation in this subgroup #mmsm

X post image

4 Jun 2023

#ASCO23 | Yael Cohen, @SouraskyMedCtr, presents the initial results of combining teclistamab + talquetamab (BCMA + GPRC5D bsAb) in triple-class exposed #myeloma and some also previously exposed to a BCMA agent. Safety profile considered similar to monotherapy. #mmsm

X post image

3 Jun 2023

#ASCO23 | Of note, 55% of patients experienced Gr3-4 neutropenia despite reduced Pom dose (2 mg).
There is a need to continue exploring combination therapies for post-HSCT maintenance, particularly for high-risk patients #mmsm #bmtsm

X post image

3 Jun 2023

#ASCO23 | @AjayNookaMD presents the data of KPd as maintenance tx for HRMM after a median f-up of 30 months. Primary endpoint: ≥CR rate #mmsm

X post image

3 Jun 2023

RT @HadidiSamer: #mmsm #ASCO23 @asco plasma cell dyscrasia oral session - Discussing the 2nd 3 abstracts

Nice summary of trials vein to ve…

X post image

3 Jun 2023

#ASCO23 | Dr. Andrzej J. Jakubowiak raised the question of whether Elo-KRd could substitute Dara-KRd in first-line (with longer follow-up and positive results) #mmsm

X post image

3 Jun 2023

#ASCO23 | Stefan Knop, @Uni_WUE, presents the results of Elo-KRd vs KRd induction in >500 patients from Germany and Austria. Adding elotuzumab improved VGPR and MRD neg rates in a cohort that included 22-25% of HRMM. Ongoing study #mmsm

X post image

2 Jun 2023

RT @bdermanmd: Are you ready for an #ASCO23 myeloma megathread? Here are 10 important abstracts to tune into to learn more (esp. with so li…

X post image

2 Jun 2023

RT @HadidiSamer: #mmsm #ASCO23 @ASCO @ShakiraG_MBBS Educational session
Nice summary of myeloma specific frailty score 👇Age is alone not e…

X post image

1 Jun 2023

🗣 The #MM Hub will be virtually covering the #ASCO23 Hybrid Congress from June 2-6, 2023! 

Keep an eye on our socials for updates throughout the congress! 

#cancertreatment #mmsm #multiplemyeloma

X post image

31 May 2023

This application is based on the results of the CARTITUDE-4 phase III trial in patients who have received 1–3 prior lines of therapy.

The results of CARTITUDE-4 will be presented at #ASCO23.

#myeloma #mmsm

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2023 American Society of Clinical Oncology

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox